-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Currently, transarterial chemoembolization (TACE) is the recommended first-line therapy for unresectable hepatocellular carcinoma (HCC), and overall survival (OS) is a standard indicator for evaluating prognosi.
However, the common practice of repeating TACE "on demand" raises the question of whether the surrogacy of OR should depend on response after initial surgery (initial OR) or the best response achieved in repeat surgery (optimal OR.
The OR value after initial TACE is more likely to apply to small single nodules, while large or multiple nodules usually require repeated TACE, and the optimal ORR becomes more intuitive and accurat.
Recently, a study published in European Radiology used individual data to explore the prognostic value of initial and optimal ORR and its compensation with tumor burden, providing a more accurate clinical evaluation of patient treatment effect and stratificatio.
A total of 1549 eligible patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh score ≤7, and performance status score ≤1 accepted from 17 academic hospitals between January 2010 and May 2016 Patients treated with TACE were retrospectively analyze.
Both initial and optimal ORRs interacted with tumor burde.
This study suggests that the optimal timing to assess ORR should be based on tumor burde.
Original source:
Dongdong Xia, Qiuhe Wang, Wei Ba.
